Compare HTBK & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HTBK | NMRA |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 576.1M |
| IPO Year | 1998 | 2023 |
| Metric | HTBK | NMRA |
|---|---|---|
| Price | $12.23 | $3.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $12.88 | $8.00 |
| AVG Volume (30 Days) | 531.6K | ★ 1.7M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | N/A | ★ 57.85 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $3,561,000.00 | N/A |
| Revenue This Year | $7.80 | N/A |
| Revenue Next Year | $5.51 | N/A |
| P/E Ratio | $23.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.09 | $0.62 |
| 52 Week High | $13.83 | $3.65 |
| Indicator | HTBK | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.70 | 53.82 |
| Support Level | $11.84 | $1.53 |
| Resistance Level | $12.89 | $3.25 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 16.29 | 32.58 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.